SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andrea Chiricozzi, Dante Caposiena, Virginia Garofalo, Maria Vittoria Cannizzaro, Sergio Chimenti, Rosita Saraceno, A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast, Expert Review of Clinical Immunology, 2016, 12, 3, 237

    CrossRef

  2. 2
    Ennio Lubrano, Fabio Massimo Perrotta, Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis, Drugs, 2016, 76, 6, 663

    CrossRef

  3. 3
    Francesco Caso, Antonio Del Puente, Rosario Peluso, Paolo Caso, Nicolò Girolimetto, Aurora Del Puente, Raffaele Scarpa, Luisa Costa, Emerging drugs for psoriatic arthritis, Expert Opinion on Emerging Drugs, 2016, 21, 1, 69

    CrossRef

  4. 4
    Kaihe Xiong, Xingling Ma, Na Cao, Lei Liu, Lili Sun, Qiaogen Zou, Ping Wei, Identification, characterization and HPLC quantification of impurities in apremilast, Anal. Methods, 2016, 8, 8, 1889

    CrossRef

  5. 5
    Raquel Salazar-Méndez, Taygan Yilmaz, Miguel Cordero-Coma, Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development, Expert Opinion on Investigational Drugs, 2016, 25, 2, 195

    CrossRef

  6. 6
    Zenas Z. N. Yiu, Richard B. Warren, Novel Oral Therapies for Psoriasis and Psoriatic Arthritis, American Journal of Clinical Dermatology, 2016,

    CrossRef

  7. 7
    Damien D. Pearse, Zoë A. Hughes, PDE4B as a microglia target to reduce neuroinflammation, Glia, 2016, 64, 6
  8. 8
    Peter H. Schafer, Francesca Truzzi, Anastasia Parton, Lei Wu, Jolanta Kosek, Ling-Hua Zhang, Gerald Horan, Annalisa Saltari, Marika Quadri, Roberta Lotti, Alessandra Marconi, Carlo Pincelli, Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex, Cellular Signalling, 2016,

    CrossRef

  9. 9
    Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K.-C. Liu, Sarah J. Fink, Christopher J. O’Donnell, Synthetic approaches to the 2014 new drugs, Bioorganic & Medicinal Chemistry, 2016, 24, 9, 1937

    CrossRef

  10. 10
    Maria Sole Chimenti, Talia Gramiccia, Rosita Saraceno, Luca Bianchi, Virginia Garofalo, Oreste Buonomo, Roberto Perricone, Sergio Chimenti, Andrea Chiricozzi, Apremilast for the treatment of psoriasis, Expert Opinion on Pharmacotherapy, 2015, 16, 13, 2083

    CrossRef

  11. 11
    Alejandro Souto, Juan J Gómez-Reino, Apremilast for the treatment of psoriatic arthritis, Expert Review of Clinical Immunology, 2015, 11, 12, 1281

    CrossRef

  12. 12
    Jennifer C Cather, Elizabeth J Horn, Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies, Clinical Investigation, 2015, 5, 9, 777

    CrossRef

  13. 13
    Miguel Perez-Aso, M. Carmen Montesinos, Aránzazu Mediero, Tuere Wilder, Peter H. Schafer, Bruce Cronstein, Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  14. 14
    Hunar Abdulrahim, Samuel Thistleton, Adewale O Adebajo, Tim Shaw, Christopher Edwards, Alvin Wells, Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis, Expert Opinion on Pharmacotherapy, 2015, 16, 7, 1099

    CrossRef

  15. 15
    Emma D. Deeks, Apremilast: A Review in Psoriasis and Psoriatic Arthritis, Drugs, 2015, 75, 12, 1393

    CrossRef

  16. 16
    Laura J. Kopplin, Amde S. Shifera, Eric B. Suhler, Phoebe Lin, Biological Response Modifiers in the Treatment of Noninfectious Uveitis, International Ophthalmology Clinics, 2015, 55, 2, 19

    CrossRef

  17. 17
    Lei Guo, Lifeng Luo, Rui Ju, Chen Chen, Lei Zhu, Juan Li, Xiaoli Yu, Caiying Ye, Dechang Zhang, Carboxyamidotriazole: A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases, European Journal of Pharmacology, 2015, 746, 14

    CrossRef

  18. 18
    Silvia Martina Ferrari, Ilaria Ruffilli, Michele Colaci, Alessandro Antonelli, Clodoveo Ferri, Poupak Fallahi, CXCL10 in psoriasis, Advances in Medical Sciences, 2015, 60, 2, 349

    CrossRef

  19. 19
    Noah P. Zimmerman, Ishan Roy, Andrew D. Hauser, Jessica M. Wilson, Carol L. Williams, Michael B. Dwinell, Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells, Molecular Carcinogenesis, 2015, 54, 3
  20. 20
    Swapna Busa, Arthur Kavanaugh, Drug safety evaluation of apremilast for treating psoriatic arthritis, Expert Opinion on Drug Safety, 2015, 14, 6, 979

    CrossRef

  21. 21
    C. Paul, J. Cather, M. Gooderham, Y. Poulin, U. Mrowietz, C. Ferrandiz, J. Crowley, C. Hu, R.M. Stevens, K. Shah, R.M. Day, G. Girolomoni, A.B. Gottlieb, Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2), British Journal of Dermatology, 2015, 173, 6
  22. 22
    Zenas ZN Yiu, Richard B Warren, Efficacy and safety of emerging immunotherapies in psoriasis, Immunotherapy, 2015, 7, 2, 119

    CrossRef

  23. 23
    Jennifer L. Barnas, Christopher T. Ritchlin, Etiology and Pathogenesis of Psoriatic Arthritis, Rheumatic Disease Clinics of North America, 2015, 41, 4, 643

    CrossRef

  24. 24
    Miles Houslay, Hypertension linked to PDE3A activation, Nature Genetics, 2015, 47, 6, 562

    CrossRef

  25. 25
    Arnald Alonso, Eugeni Domènech, Antonio Julià, Julián Panés, Valle García-Sánchez, Pilar Nos Mateu, Ana Gutiérrez, Fernando Gomollón, Juan L. Mendoza, Esther Garcia-Planella, Manuel Barreiro-de Acosta, Fernando Muñoz, Maribel Vera, Cristina Saro, Maria Esteve, Montserrat Andreu, Maria Chaparro, Josep Manyé, Eduard Cabré, María López-Lasanta, Raül Tortosa, Josep Lluís Gelpí, Andrés C. García-Montero, Jaume Bertranpetit, Devin Absher, Richard M. Myers, Sara Marsal, Javier P. Gisbert, Identification of Risk Loci for Crohn’s Disease Phenotypes Using a Genome-Wide Association Study, Gastroenterology, 2015, 148, 4, 794

    CrossRef

  26. 26
    Małgorzata Mazur, Jacek Karczewski, Martha Lodyga, Ryszard Żaba, Zygmunt Adamski, Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis, Journal of Dermatological Treatment, 2015, 26, 4, 326

    CrossRef

  27. 27
    Ahmet Gül, Pathogenesis of Behçet’s disease: autoinflammatory features and beyond, Seminars in Immunopathology, 2015, 37, 4, 413

    CrossRef

  28. 28
    Carina Jørgensen, Saiqa Yasmeen, Helle K. Iversen, Christina Kruuse, Phosphodiesterase4D (PDE4D) — A risk factor for atrial fibrillation and stroke?, Journal of the Neurological Sciences, 2015, 359, 1-2, 266

    CrossRef

  29. 29
    Melinda Gooderham, Kim Papp, Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast, BioDrugs, 2015, 29, 5, 327

    CrossRef

  30. 30
    Peter H. Schafer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra, The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1), Journal of Immunology Research, 2015, 2015, 1

    CrossRef

  31. 31
    Carl Orr, Douglas James Veale, Therapeutic targets in psoriatic arthritis, International Journal of Clinical Rheumatology, 2015, 10, 6, 489

    CrossRef

  32. 32
    Dennis Cada, Kyle Ingram, Danial Baker, Apremilast, Hospital Pharmacy, 2014, 49, 8, 752

    CrossRef

  33. 33
    Sowmya Varada, Suzanne J Tintle, Alice B Gottlieb, Apremilast for the treatment of psoriatic arthritis, Expert Review of Clinical Pharmacology, 2014, 7, 3, 239

    CrossRef

  34. 34
    P.H. Schafer, A. Parton, L. Capone, D. Cedzik, H. Brady, J.F. Evans, H.-W. Man, G.W. Muller, D.I. Stirling, R. Chopra, Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity, Cellular Signalling, 2014, 26, 9, 2016

    CrossRef

  35. 35
    Philip J. Mease, Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis, Rheumatology and Therapy, 2014, 1, 1, 1

    CrossRef

  36. 36
    Raewyn M. Poole, Anita D. Ballantyne, Apremilast: First Global Approval, Drugs, 2014, 74, 7, 825

    CrossRef

  37. 37
    Benjamin H Kaffenberger, Grace L Lee, Kelly Tyler, Derek V Chan, Wael Jarjour, Maria E Ariza, Marshall V Williams, Henry K Wong, Current and potential immune therapies and vaccines in the management of psoriasis, Human Vaccines & Immunotherapeutics, 2014, 10, 4, 876

    CrossRef

  38. 38
    Susanne C. Feil, Jessica K. Holien, Craig J. Morton, Nancy C. Hancock, Philip E. Thompson, Michael W. Parker, Discovery of Phosphodiesterase-4 Inhibitors: Serendipity and Rational Drug Design, Australian Journal of Chemistry, 2014, 67, 12, 1780

    CrossRef

  39. 39
    Naoto Ishii, Hisashi Wakita, Manabu Shirato, Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice, Journal of Dermatological Science, 2014, 76, 3, 263

    CrossRef

  40. 40
    Knut Schäkel, Thomas Döbel, Ina Bosselmann, Future treatment options for atopic dermatitis – Small molecules and beyond, Journal of Dermatological Science, 2014, 73, 2, 91

    CrossRef

  41. 41
    A. G. Soboleva, A. V. Mesentsev, S. A. Bruskin, Genetically modified animals as models of the pathological processes in psoriasis, Molecular Biology, 2014, 48, 4, 508

    CrossRef

  42. 42
    Jakob Theorell, Anna-Lena Gustavsson, Bianca Tesi, Kristmundur Sigmundsson, Hans-Gustaf Ljunggren, Thomas Lundbäck, Yenan T. Bryceson, Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation, Cancer Immunology, Immunotherapy, 2014, 63, 6, 627

    CrossRef

  43. 43
    Barry J Sheane, Vinod Chandran, Investigational drugs for treating psoriatic arthritis, Expert Opinion on Investigational Drugs, 2014, 23, 7, 1001

    CrossRef

  44. 44
    Philip J. Mease, April W. Armstrong, Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis, Drugs, 2014, 74, 4, 423

    CrossRef

  45. 45
    Renata Baronaite Hansen, Arthur Kavanaugh, Novel Treatments with Small Molecules in Psoriatic Arthritis, Current Rheumatology Reports, 2014, 16, 9

    CrossRef

  46. 46
    Alejandro Souto, Juan J Gómez-Reino, Potential role of apremilast for the treatment of psoriatic arthritis, International Journal of Clinical Rheumatology, 2014, 9, 3, 259

    CrossRef

  47. 47
    Oliver FitzGerald, Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis, Nature Reviews Rheumatology, 2014, 10, 7, 385

    CrossRef

  48. 48
    Brian R Leaker, Dave Singh, Ferhana Y Ali, Peter J Barnes, Brian O’Connor, The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma, BMC Pulmonary Medicine, 2014, 14, 1, 166

    CrossRef

  49. 49
    Barry J Sheane, Vinod Chandran, The future of treatment for psoriatic arthritis, International Journal of Clinical Rheumatology, 2014, 9, 1, 59

    CrossRef

  50. 50
    Phoebe Lin, Eric B. Suhler, James T. Rosenbaum, The Future of Uveitis Treatment, Ophthalmology, 2014, 121, 1, 365

    CrossRef

  51. 51
    A. Kavanaugh, P. J. Mease, J. J. Gomez-Reino, A. O. Adebajo, J. Wollenhaupt, D. D. Gladman, E. Lespessailles, S. Hall, M. Hochfeld, C. Hu, D. Hough, R. M. Stevens, G. Schett, Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor, Annals of the Rheumatic Diseases, 2014, 73, 6, 1020

    CrossRef

  52. 52
    Filip Van den Bosch, Atul Deodhar, Treatment of spondyloarthritis beyond TNF-alpha blockade, Best Practice & Research Clinical Rheumatology, 2014, 28, 5, 819

    CrossRef

  53. 53
    Matthew Hoffmann, Claudia Kasserra, Josephine Reyes, Peter Schafer, Jolanta Kosek, Lori Capone, Anastasia Parton, Heasook Kim-Kang, Sekhar Surapaneni, Gondi Kumar, Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration, Cancer Chemotherapy and Pharmacology, 2013, 71, 2, 489

    CrossRef

  54. 54
    Joan Paul, Clare E. Foss, Stefanie A. Hirano, Tina D. Cunningham, David M. Pariser, An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series, Journal of the American Academy of Dermatology, 2013, 68, 2, 255

    CrossRef

  55. 55
    Riku Korhonen, Tuija Hömmö, Tiina Keränen, Mirka Laavola, Mari Hämäläinen, Katriina Vuolteenaho, Lauri Lehtimäki, Hannu Kankaanranta, Eeva Moilanen, Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1, British Journal of Pharmacology, 2013, 169, 7
  56. 56
    David Chandler, Anthony Bewley, Biologics in Dermatology, Pharmaceuticals, 2013, 6, 4, 557

    CrossRef

  57. 57
    Wolf-Henning Boehncke, Alan Menter, Burden of Disease: Psoriasis and Psoriatic Arthritis, American Journal of Clinical Dermatology, 2013, 14, 5, 377

    CrossRef

  58. 58
    K.A. Papp, R. Kaufmann, D. Thaçi, C. Hu, D. Sutherland, P. Rohane, Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 3
  59. 59
    E. Pathan, S. Abraham, E. Van Rossen, R. Withrington, A. Keat, P. J. Charles, E. Paterson, M. Chowdhury, C. McClinton, P. C. Taylor, Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis, Annals of the Rheumatic Diseases, 2013, 72, 9, 1475

    CrossRef

  60. 60
    Peggy Jacques, Filip Van den Bosch, Emerging therapies for rheumatoid arthritis, Expert Opinion on Emerging Drugs, 2013, 18, 2, 231

    CrossRef

  61. 61
    Vibeke Strand, David Fiorentino, ChiaChi Hu, Robert M Day, Randall M Stevens, Kim A Papp, Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study, Health and Quality of Life Outcomes, 2013, 11, 1, 82

    CrossRef

  62. 62
    Yasir A. Syed, Alexandra Baer, Matthias P. Hofer, Ginez A. González, Jon Rundle, Szymon Myrta, Jeffrey K. Huang, Chao Zhao, Moritz J. Rossner, Matthew W. B. Trotter, Gert Lubec, Robin J. M. Franklin, Mark R. Kotter, Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination, EMBO Molecular Medicine, 2013, 5, 12
  63. 63
    Peter H. Schafer, Robert M. Day, Novel systemic drugs for psoriasis: Mechanism of action for apremilast, a specific inhibitor of PDE4, Journal of the American Academy of Dermatology, 2013, 68, 6, 1041

    CrossRef

  64. 64
    Miriam Wittmann, Philip S. Helliwell, Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases, Dermatology and Therapy, 2013, 3, 1, 1

    CrossRef

  65. 65
    Amadeu Gavaldà, Richard S Roberts, Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012), Expert Opinion on Therapeutic Patents, 2013, 23, 8, 997

    CrossRef

  66. 66
    Sarah Dubois Declercq, Roxane Pouliot, Promising New Treatments for Psoriasis, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  67. 67
    Petr A. Zhmurov, Alexey Yu. Sukhorukov, Vladimir I. Chupakhin, Yulia V. Khomutova, Sema L. Ioffe, Vladimir A. Tartakovsky, Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues, Organic & Biomolecular Chemistry, 2013, 11, 46, 8082

    CrossRef

  68. 68
    Emily Yiping Gan, Wei-Sheng Chong, Hong Liang Tey, Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents, BioDrugs, 2013, 27, 4, 359

    CrossRef

  69. 69
    Brandon Shutty, Cameron West, Megan Pellerin, Steven Feldman, Apremilast as a treatment for psoriasis, Expert Opinion on Pharmacotherapy, 2012, 13, 12, 1761

    CrossRef

  70. 70
    Gregory P. McLENNAN, Iyad KHOURDAJI, Kim A. KILLINGER, Judith A. BOURA, Kenneth M. PETERS, Apremilast in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Study, LUTS: Lower Urinary Tract Symptoms, 2012, 4, 3
  71. 71
    Peter Schafer, Apremilast mechanism of action and application to psoriasis and psoriatic arthritis, Biochemical Pharmacology, 2012, 83, 12, 1583

    CrossRef

  72. 72
    Peter CM van de Kerkhof, Apremilast: a step forward in the treatment of psoriasis?, The Lancet, 2012, 380, 9843, 708

    CrossRef

  73. 73
    Noah P. Zimmerman, Suresh N. Kumar, Jerrold R. Turner, Michael B. Dwinell, Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA, Inflammatory Bowel Diseases, 2012, 18, 6
  74. 74
    Kim Papp, Jennifer C Cather, Les Rosoph, Howard Sofen, Richard G Langley, Robert T Matheson, ChiaChi Hu, Robert M Day, Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial, The Lancet, 2012, 380, 9843, 738

    CrossRef

  75. 75
    Iris Ahronowitz, Joanna Harp, Kanade Shinkai, Etiology and Management of Pyoderma Gangrenosum, American Journal of Clinical Dermatology, 2012, 13, 3, 191

    CrossRef

  76. 76
    Hila Yehuda, Yoram Soroka, Marina Zlotkin-Frušić, Amos Gilhar, Yoram Milner, Snait Tamir, Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin, Inflammation Research, 2012, 61, 7, 735

    CrossRef

  77. 77
    Johann E. Gudjonsson, Andrew Johnston, Charles N. Ellis, Novel systemic drugs under investigation for the treatment of psoriasis, Journal of the American Academy of Dermatology, 2012, 67, 1, 139

    CrossRef

  78. 78
    Georg Schett, Jurgen Wollenhaupt, Kim Papp, Rik Joos, Jude F. Rodrigues, Adele R. Vessey, ChiaChi Hu, Randall Stevens, Kurt L. de Vlam, Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study, Arthritis & Rheumatism, 2012, 64, 10
  79. 79
    Lars Svensson, Mads A Røpke, Hanne Norsgaard, Psoriasis drug discovery: methods for evaluation of potential drug candidates, Expert Opinion on Drug Discovery, 2012, 7, 1, 49

    CrossRef

  80. 80
    A Buenestado, S Grassin-Delyle, F Guitard, E Naline, C Faisy, D Israël-Biet, E Sage, JF Bellamy, H Tenor, P Devillier, Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide, British Journal of Pharmacology, 2012, 165, 6
  81. 81
    Robert P Baughman, Hilario Nunes, Therapy for sarcoidosis: evidence-based recommendations, Expert Review of Clinical Immunology, 2012, 8, 1, 95

    CrossRef

  82. 82
    Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar, Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies, Expert Opinion on Pharmacotherapy, 2012, 13, 4, 473

    CrossRef

  83. 83
    B Omar, E Banke, M Ekelund, S Frederiksen, E Degerman, Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity, Nutrition and Diabetes, 2011, 1, 8, e13

    CrossRef

  84. 84
    E. Bargagli, C. Olivieri, P. Rottoli, Cytokine modulators in the treatment of sarcoidosis, Rheumatology International, 2011, 31, 12, 1539

    CrossRef

  85. 85
    Matthew Hoffmann, Gondi Kumar, Peter Schafer, Dorota Cedzik, Lori Capone, Kei-Lai Fong, Zheming Gu, Dennis Heller, Hao Feng, Sekhar Surapaneni, Oscar Laskin, Anfan Wu, Disposition, metabolism and mass balance of [14C]apremilast following oral administration, Xenobiotica, 2011, 41, 12, 1063

    CrossRef

  86. 86
    Alexandre Chigaev, Yelena Smagley, Larry A Sklar, Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion, BMC Immunology, 2011, 12, 1, 28

    CrossRef

  87. 87
    Karin Stenderup, Cecilia Rosada, Lene Alifrangis, Søren Andersen, Tomas Norman Dam, Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A, Experimental Dermatology, 2011, 20, 5
  88. 88
    Miles Houslay, Marco Conti, Phosphodiesterase 4D, cAMP specific, AfCS-Nature Molecule Pages, 2010,

    CrossRef

  89. 89
    Etzer Darout, Elnaz Menhaji-Klotz, Thomas A. Chappie, PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects,